The molecular basis of retinoids' use in breast cancer chemoprevention

Cellular Oncology

Volumn 29, Issue 3, 2007, Pages 183-184

  Karamouzis, Michalis V ^a,b   Konstantinopoulos, Panagiotis A ^a,c   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; FENRETINIDE; RETINOID; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOWN REGULATION; DRUG MECHANISM; EDITORIAL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, RETINOIC ACID; RETINOIDS; TRANSCRIPTION FACTOR AP-1;

EID: 34249820790     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. A. Husdal, G. Bukholm and I.R. Bukholm, The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient, Cell. Oncol. 28 (2006), 107-116.
2. E.A. Janssen, P.J. van Diest, H. Soiland et al., Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years, Cell. Oncol. 28 (2006), 295-303.
3. M.V. Karamouzis and A.G. Papavassiliou, Retinoid receptor cross-talk in respiratory epithelium cancer chemoprevention, Trends Mol. Med. 11 (2005), 10-16.
4. M.S. Kortenhorst, M.A. Carducci and S. Shabbeer, Acetylation and histone deacetylase inhibitors in cancer, Cell. Oncol. 28 (2006), 191-222.
5. K.I. Pritchard, Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?, Ann. Oncol. 17 (2006), 1035-1036.
6. A.M. Simeone, Y.J. Li, L.D. Broemeling, M.M. Johnson, M. Tuna and A.M. Tari, Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells, Cancer Res. 64 (2004), 1224-1228.
7. U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M.G. Di Mauro, A. Costa, E. Marubini, M.B. Sporn and G. De Palo, Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer, Ann. Oncol. 17 (2006), 1065-1071.
8. J.M. Wu, A.M. Di Pietrantonio and T.C. Hsieh, Mechanism of fenretinide (4-HPR)-induced cell death, Apoptosis 6 (2001), 377-388.